Patents by Inventor Lee Patient

Lee Patient has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS
    Publication number: 20180194763
    Abstract: The compounds of formula (I) are inhibitors of SSAO activity wherein V, W, X, Y, Z, R1 and R2 are as defined in the claims.
    Type: Application
    Filed: March 5, 2018
    Publication date: July 12, 2018
    Applicant: PROXIMAGEN LIMITED
    Inventors: Max Espensen, Lee Patient, David Evans, Iain Simpson, Edward Savory
  • Imidazo[4,5-C]pyridine and pyrrolo[2,3-C]pyridine derivatives as SSAO inhibitors
    Patent number: 9951068
    Abstract: The compounds of formula (I) are inhibitors of SSAO activity wherein V, W, X, Y, Z, R1 and R2 are as defined in the claims.
    Type: Grant
    Filed: May 11, 2017
    Date of Patent: April 24, 2018
    Assignee: PROXIMAGEN LIMITED
    Inventors: Max Espensen, Lee Patient, David Evans, Iain Simpson, Edward Savory
  • IMIDAZO[4,5-C]PYRIDINE DERIVED SSAO INHIBITORS
    Publication number: 20170362218
    Abstract: A compound as set out in claim 1, and the use of the same in therapy.
    Type: Application
    Filed: September 17, 2015
    Publication date: December 21, 2017
    Inventors: Max Espensen, Lee Patient, Edward Savory
  • IMIDAZO[4,5-C]PYRIDINE DERIVED SSAO INHIBITORS
    Publication number: 20170275281
    Abstract: A compound of formula (I) or a pharmaceutically acceptable salt, or N-oxide thereof and the use of the same in therapy: wherein Z, Y, R1, W, V, and R3 are as defined in claim 1.
    Type: Application
    Filed: September 17, 2015
    Publication date: September 28, 2017
    Inventors: Lee Patient, Iain Simpson, Edward Savory
  • IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS
    Publication number: 20170247378
    Abstract: The compounds of formula (I) are inhibitors of SSAO activity wherein V, W, X, Y, Z, R1 and R2 are as defined in the claims.
    Type: Application
    Filed: May 11, 2017
    Publication date: August 31, 2017
    Inventors: Max Espensen, Lee Patient, David Evans, Iain Simpson, Edward Savory
  • CXCR4 Receptor Antagonists
    Publication number: 20170226106
    Abstract: The compounds of formula (I) are antagonists of the CXCR4 receptor Wherein R1, X, Y and R2 are as defined in the claims.
    Type: Application
    Filed: April 26, 2017
    Publication date: August 10, 2017
    Inventors: Edward Daniel Savory, Alison Stewart, Allison Carley, Giles Brown, Iain Simpson, Kathryn Oliver, Lee Patient, Michael Higginbottom, Andrew Graham Cole
  • Imidazo[4,5-C]pyridine and pyrrolo[2,3-C]pyridine derivatives as SSAO inhibitors
    Patent number: 9676769
    Abstract: The compounds of formula (I) are inhibitors of semicarbazide-sensitive amine oxidase (SSAO) activity useful in the treatment of inflammation, an inflammatory disease, an immune or an autoimmune disorder, or inhibition of tumor growth.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: June 13, 2017
    Assignee: Proximagen Limited
    Inventors: Max Espensen, Lee Patient, David Evans, Iain Simpson, Edward Savory
  • Compounds
    Patent number: 9580415
    Abstract: The compound of formula (I) are inhibitors of SSAO activity (Formula (I)) wherein the terms Y, Z, W, R1 and R2 are defined in the claims.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: February 28, 2017
    Assignee: Proximagen Limited
    Inventors: Lee Patient, David Evans, Iain Simpson, Allison Powell
  • NEW COMPOUNDS
    Publication number: 20160326172
    Abstract: The present invention relates to compounds which are inhibitors of SSAO activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment or prevention of medical conditions wherein inhibition of SSAO activity is beneficial, such as inflammatory diseases, immune disorders and the inhibition of tumor growth.
    Type: Application
    Filed: July 20, 2016
    Publication date: November 10, 2016
    Inventors: Max Espensen, Lee Patient, David Evans, Edward Savory, Iain Simpson
  • Substituted imidazo[4,5-c]pyridine compounds and compositions thereof
    Patent number: 9428498
    Abstract: The present invention relates to compounds which are inhibitors of SSAO activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment or prevention of medical conditions wherein inhibition of SSAO activity is beneficial, such as inflammatory diseases, immune disorders and the inhibition of tumor growth.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: August 30, 2016
    Assignee: Proximagen Limited
    Inventors: Max Espensen, Lee Patient, David Evans, Edward Savory, Iain Simpson
  • CXCR4 receptor antagonists
    Patent number: 9353086
    Abstract: Disclosed are compounds that are antagonists of the CXCR4 receptor.
    Type: Grant
    Filed: October 13, 2011
    Date of Patent: May 31, 2016
    Assignee: Proximagen Limited
    Inventors: Edward Daniel Savory, Alison Stewart, Allison Carley, Giles Brown, Iain Simpson, Kathryn Oliver, Lee Patient, Michael Higginbottom, Andrew Graham Cole
  • CXCR4 Receptor Antagonists
    Publication number: 20160046606
    Abstract: The compounds of formula (I) are antagonists of the CXCR4 receptor Wherein R1, X, Y and R2 are as defined in the claims.
    Type: Application
    Filed: September 14, 2015
    Publication date: February 18, 2016
    Inventors: Edward Daniel Savory, Alison Stewart, Allison Carley, Giles Brown, Iain Simpson, Kathryn Oliver, Lee Patient, Michael Higginbottom, Andrew Graham Cole
  • IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS
    Publication number: 20160046622
    Abstract: The compounds of formula (I) are inhibitors of semicarbazide-sensitive amine oxidase (SSAO) activity useful in the treatment of inflammation, an inflammatory disease, an immune or an autoimmune disorder, or inhibition of tumour growth.
    Type: Application
    Filed: March 13, 2014
    Publication date: February 18, 2016
    Inventors: Max Espensen, Lee Patient, David Evans, Iain Simpson, Edward Savory
  • NEW COMPOUNDS
    Publication number: 20160024080
    Abstract: The compound of formula (I) are inhibitors of SSAO activity (Formula (I)) wherein the terms Y, Z, W, R1 and R2 are defined in the claims.
    Type: Application
    Filed: March 13, 2014
    Publication date: January 28, 2016
    Inventors: Lee Patient, David Evans, Iain Simpson, Allison Powell
  • NEW COMPOUNDS
    Publication number: 20140275040
    Abstract: The present invention relates to compounds which are inhibitors of SSAO activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment or prevention of medical conditions wherein inhibition of SSAO activity is beneficial, such as inflammatory diseases, immune disorders and the inhibition of tumor growth.
    Type: Application
    Filed: March 13, 2014
    Publication date: September 18, 2014
    Applicant: Proximagen Limited
    Inventors: Max Espensen, Lee Patient, David Evans, Edward Savory, Iain Simpson
  • CXCR4 Receptor Antagonists
    Publication number: 20130289020
    Abstract: Disclosed are compounds that are antagonists of the CXCR4 receptor.
    Type: Application
    Filed: October 13, 2011
    Publication date: October 31, 2013
    Applicant: Proximagen Limited
    Inventors: Edward Daniel Savory, Allson Stewart, Allison Cartey, Giles Brown, Iain Simpson, Kathryn Oliver, Lee Patient, Michael Higginbottom, Andrew Graham Cole
  • Tetrahydrofuro[3,2-b] pyrrol-3-one intermediates
    Patent number: 8039641
    Abstract: The present invention relates to a process for preparing a compound of formula (Ia), (Ib), (Ic) or (Id), or a pharmaceutically acceptable salt, hydrate, solvate, complex or prodrug thereof, said process comprising the steps of: (A) (i) treating a compound of formula (IVa), where R48 is alkyl or tosyl, with an oxidizing agent to form a compound of formula (Va); and (ii) converting said compound of formula (Va) to a compound of formula (Ia) or (Ic); or (B) (i) treating a compound of formula (IVb), where R48 is alkyl or tosyl, with an oxidizing agent to form a compound of formula (Vb); and (ii) converting said compound of formula (Vb) to a compound of formula (Ib) or (Id).
    Type: Grant
    Filed: January 8, 2009
    Date of Patent: October 18, 2011
    Assignee: Amura Therapeutics Limited
    Inventors: Martin Quibell, James Nally, Lee Patient, Yikang Wang, Claudio Dagostin, John Paul Watts
  • Tetrahydrofuro[3,2-b] pyrrol-3-one intermediates
    Publication number: 20090192322
    Abstract: The present invention relates to a process for preparing a compound of formula (Ia), (Ib), (Ic) or (Id), or a pharmaceutically acceptable salt, hydrate, solvate, complex or prodrug thereof, said process comprising the steps of: (A) (i) treating a compound of formula (IVa), where R48 is alkyl or tosyl, with an oxidising agent to form a compound of formula (Va); and (ii) converting said compound of formula (Va) to a compound of formula (Ia) or (Ic); or (B) (i) treating a compound of formula (IVb), where R48 is alkyl or tosyl, with an oxidising agent to form a compound of formula (Vb); and (ii) converting said compound of formula (Vb) to a compound of formula (Ib) or (Id).
    Type: Application
    Filed: January 8, 2009
    Publication date: July 30, 2009
    Applicant: Amura Therapeutics Limited
    Inventors: Martin Quibell, James Nally, Lee Patient, Yikang Wang, Claudio Dagostin, John Paul Watts
  • Biologically active compounds
    Publication number: 20090131502
    Abstract: The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions comprising compounds of formula (I), and the use of such compounds in the treatment of a disease selected from osteoporosis, Paget's disease, Chagas's disease, malaria, gingival diseases, hypercalaemia, metabolic bone disease and diseases involving matrix or cartilate degradation.
    Type: Application
    Filed: February 25, 2008
    Publication date: May 21, 2009
    Inventors: Martin Quibell, John Paul Watts, Yikang Wang, Lee Patient, Jonathan R. Heal
  • Azacyclic compounds as inhibitors of sensory neurone specific channels
    Publication number: 20070043024
    Abstract: Compounds of the formula (I), and pharmaceutically acceptable salts thereof, are found to be antagonists of SNS sodium channels. They are therefore useful as analgesic and neuroprotective agents wherein: X is —N— or —CH—; n is from 0 to 3.
    Type: Application
    Filed: July 7, 2004
    Publication date: February 22, 2007
    Inventors: Richard Hamlyn, Michael Huckstep, Rosemary Lynch, Stephen Stokes, David Tickle, Lee Patient